|Year : 2017 | Volume
| Issue : 2 | Page : 10-16
MicroRNAs in hepatocellular carcinoma – therapeutics and beyond: A systematic review
Gaurav Roy1, Papai Roy2
1 Molecular Genetics Laboratory, Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India
2 Molecular Genetics and Development, Institut de Recherches Cliniques de Montreal, Montreal, Canada
|Date of Web Publication||23-May-2017|
Molecular Genetics Laboratory, Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi
Source of Support: None, Conflict of Interest: None
Hepatocellular carcinoma (HCC) causes major cancer-related deaths worldwide. The current therapeutic strategies pitted against early HCC are woefully inadequate with surgical interventions, radiation therapy, and chemotherapy to suffice for. Therefore, the quest for novel, effective, and decisive screening tools is paramount. In context, microRNAs (miRNAs) have emerged as useful biomarkers in HCC. Accordingly, PubMed, Medline, Embase, and Cochrane databases were explored for relevant literature in English with combination of keywords “microRNA and hepatocellular carcinoma,” “microRNA and diagnosis and hepatocellular carcinoma,” “microRNA and prognosis and hepatocellular carcinoma,” “microRNA and survival and hepatocellular carcinoma,” and “microRNA and therapy and hepatocellular carcinoma” that were extracted till January 2017. Manuscripts relating to long noncoding RNAs and other concomitant small molecules involved in HCC were excluded from the review. Studies revealed a plethora of miRNAs and their altered expression profiles being significantly implicated in the diagnosis, prognosis, recurrence, and overall survival in HCC. Several miRNAs are currently being tested in different phases of clinical trials. Efforts should aim at a better validation and establishment of miRNAs as powerful diagnostic and prognostic investigating aid for HCC. However, despite extensive research, a consensus on the universal set of miRNAs to be used as diagnostic, prognostic, or recurrence markers for HCC is yet to be achieved. In addition, various targeted approaches should focus to reduce the possibility of deleterious off-target effects of miRNAs. On this background, this systematic review discusses latest developments on miRNAs as a marker of diagnosis, prognosis, recurrence, overall survival as well as a therapeutic target in HCC (REVIEW registry216).
Keywords: Biomarkers, hepatocellular carcinoma, microRNA, survival
|How to cite this article:|
Roy G, Roy P. MicroRNAs in hepatocellular carcinoma – therapeutics and beyond: A systematic review. IJS Short Rep 2017;2:10-6
| Introduction|| |
Hepatocellular carcinoma (HCC) constitutes a global health hazard accounting for 90% of primary liver cancers, with risk factors ranging from fatty liver disease, metabolic disorders, chronic alcohol exposure, aflatoxin B1 to hepatitis B virus (HBV) or hepatitis C virus (HCV) viral infections. Recent advances in molecular therapeutics have zeroed in on identifying specific diagnostic and prognostic targets for HCC. In the context, several proteins, long noncoding RNAs (lncRNA), and microRNAs (miRNA) have been reported to exhibit therapeutic efficiency in HCC. On the aforesaid backdrop, this systematic review prospectively embellishes state of the art on miRNA as diagnostic and prognostic assessment modality in the therapeutics of HCC.
| Data Extraction and Selection Criteria|| |
Literature was probed thoroughly in PubMed, Medline, Embase, and Cochrane databases using the combination of keywords “microRNA and hepatocellular carcinoma,” “microRNA and diagnosis and hepatocellular carcinoma,” “microRNA and prognosis and hepatocellular carcinoma,” “microRNA and survival and hepatocellular carcinoma,” and “microRNA and therapy and hepatocellular carcinoma” till January 2017. The scope notes in Medline and Embase were also evaluated that warranted correct subject headings based on definitions.
Only eligible manuscripts in English were retrieved with an in-depth scrutiny on their references for related studies. No restriction was imposed on sample size, population, year of publication, or type of report. Articles pertaining to lncRNAs and other concomitant small molecules implicated in HCC were judiciously excluded from the review. The accuracy of the extracted information was ensured when two investigators (Gaurav Roy and Papai Roy) independently searched data and differences agreed on by a final consensus between them. In addition, this study was fully compliant with the PRISMA Guidelines that included a checklist of aspects incorporated for this systematic review without meta-analysis as designed by the PRISMA Group. Furthermore, our article was registered with the research registry, and subsequently, a unique identifying number (REVIEW registry216) was generated after relevant information pertaining to the nature of our study was systematically filled up.
| Involvement of MicroRNAs in Hepatocellular Carcinoma: An Overview|| |
miRNA s are 20–22 nucleotide long, endogenous, nonprotein-coding RNA molecules that are primarily associated with downregulation of its target genes. Briefly, miRNAs are generally transcribed by RNA polymerase II from the intergenic region or from the antisense orientation of the gene. This primary transcript known as pri-miRNA are generally hundred to thousand base-pairs long. Subsequent internuclear processing by Drosha/Pasha complex converts pri-miRNAs to 50–80 nucleotide long pre-miRNAs with a characteristic stem-loop structure. Contextually, exportin-5 protein is the key molecule involved in the transportation of pre-miRNAs from the nucleus to the cytoplasm. Finally, in cytoplasm, the pre-miRNA undergoes further processing by Dicer to generate an imperfect duplex whereby either strand of the duplex acts as a mature miRNA.
miRNAs target messenger RNAs (mRNA) by complementarity of bases in the 3'-untranslated region (3'UTR) of the mRNA and the miRNA sequence and prospectively recruit mRNAs to the RNA-induced silencing complex that ultimately results in the inhibition of translation or degradation of mRNA. As base-pairing takes place through few bases, one miRNA may target a number of mRNAs, and contrariwise, a single mRNA may be targeted by a number of miRNAs [Figure 1]. Functionally, miRNAs regulate various biological processes such as apoptosis, differentiation, and development. Studies indicate altered miRNA expression to be associated with the development of several cancers, prion diseases, Alzheimer's condition, and autoimmune disorders.,,,
|Figure 1: Schematic representation of the molecular mechanisms involved in microRNA biogenesis with functional implications|
Click here to view
The expression profiles of miRNAs in HCC have illustrated contrasting prospects. Reports have indicated that the abundant miR-122 as evidenced in healthy liver tissues is appreciably downregulated in HCC., In addition, miR-122 has been shown to influence the stability and transcriptional activity of p53 by modulating cyclin G1 expression. Similarly, miR-26a, downregulated in HCC, targets the positive cell cycle regulators, cyclin D2 and cyclin E2. Contrarily, a number miRNAs that are upregulated in HCC (oncomirs) such as miR-21, miR-221, and miR-222 notoriously inhibit the tumor suppression of PTEN. In this regard, miR-93 has also been demonstrated to inhibit PTEN and CDKN1A, thus activating the oncogenic c-Met/p13k/AKT pathway. Interestingly, a plethora of signaling pathways such as Wnt/β-catenin, Ras, transforming growth factor-β, JAK/STAT, and nuclear factor κB have been found to be affected by miRNA dysregulation in HCC that provides crucial functional insights into the mechanistic role played by miRNAs in HCC.
Studies on virus-mediated HCC have illustrated a differential expression of miR-122, miR-19a, and miR-223 by the oncogenic HBx protein of HBV that eventually resulted in cellular proliferation of HCC. The preS2 region of HBV mRNA is targeted by let-7 g which results in its sequestration and upregulation of its targets in host cells. In the context, the third most highly expressed miRNA in liver, miR-199a-3p, has been found to be downregulated in HBV-induced HCC. On the flip side, epithelial mesenchymal transition induced by HCV core protein was restored by overexpression of miR-30c and miR-203a in cell culture and HepG2 xenograft models.
Reports have suggested miRNAs as crucial screening tools in the diagnosis, prognosis recurrence and metastasis of HCC. Data have displayed miRNAs to be extremely stable that is evidenced in their retention in serum, plasma, urine and formalin-fixed paraffin embedded tissue samples obtained from patients. This property of stability makes miRNAs a potent biomarker, easily discernible through laboratory investigations.
| Micrornas as Diagnostic Markers in Hepatocellular Carcinoma|| |
Current clinical diagnostic methods through alpha-fetoprotein (AFP), ultrasonography, magnetic resonance imaging and computerized tomography usually detect HCC at a late stage of the disease. Therefore, establishing a panel of miRNAs as early diagnostic markers is imperative. A recent report identified seven differentially expressed miRNAs (miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-192, and miR-505) known as miRNA classifier that predicted HCC earlier than clinical diagnosis. Studies have illustrated significantly elevated serum levels of miR-122 in HCC patients as compared to healthy controls that are suggestive of its use as a marker of the disease. Similar studies depict that the combination of AFP and 3-miRNA panel (miR-92-3p, miR-107, and miR-3126-5p) is an effective diagnostic aid for early-stage and low-level AFP-HCC patients. Likewise, a 13-miRNA panel (miR-375, miR-92a, miR-10a, miR-223, miR-423, miR-23b, miR-23a, miR-342-3p, miR-99a, miR-122a, miR-125b, miR-150, let-7c) has been identified as a novel noninvasive biomarker in HBV-mediated HCC that has paved the way for the diagnosis and differentiation of HBV-induced HCC cases from healthy controls, HCV and subjects with HBV infection without HCC.
MiR-1269 has been frequently reported in HCV-induced HCC as compared to healthy controls, HCV-induced cirrhosis, and HBV-induced liver failure. Other upregulated miRNAs in HCV-induced HCC are miR-224, miR-224-3p, and miR-452. However, miR-199a-5p, miR-199a-3p, and miR-199b have been reported to be downregulated in HCV-induced HCC as compared to healthy controls, HCV-induced cirrhosis, and HBV-induced liver failure. A study in Egyptian patients established miR-122, miR-199a, and miR-16 as potential biomarkers of HCV-induced HCC.
Exosomes are extracellular vesicles that have been recently recognized as one of the vectors for intercellular communication. Exosomal miRNAs derived from HCC cells have been shown to induce cellular transformation in recipient cells. Studies on miRNA in exosomes derived from HCC cell lines detected 11 exclusive miRNAs in Hep3B-derived exosomes and 20 exclusive miRNAs in PLC/PRF/5-derived exosomes. Another study on serum exosomal miRNA has demonstrated an elevated expression of miR-18a, miR-221, miR-222, and miR-224 in HCC patients as compared to chronic HBV patients and cirrhotic patients and a lowered expression of miR-101, miR-106b, miR-122, miR-195 in HCC patients as compared to chronic HBV patients.
| Prognosis of Hepatocellular Carcinoma Through MicroRNA Signatures|| |
Accumulating evidences have displayed miRNAs as a significant prognostic aid in HCC. Differential miRNA expression has been tightly correlated with tumor size, tumor nodule, risk of metastasis, tumor invasion, recurrence, and overall survival in HCC. Studies have illustrated miR-25 to regulate the tumor nodes metastasis staging [Figure 2] in HCC. Elevated expression of miR-183 in HCC tissues has been associated with large tumor size, positive nodal status, and a higher risk of metastasis. In the same vein, an upregulation of miR-221 has been demonstrated in primary HCC with distant metastasis, whereas the converse is valid for miR-100 expression., Contrastingly, a downregulation of miR-338 in HCC has been found to be deleterious leading to the development of larger tumors, intrahepatic and distant metastases with extensive vascular invasion. Similar panel of 20 miRNAs has been reported to be concurrent with HCC recurrence and metastasis. Another recent study indicates miR-487 (mediated by heat shock factor 1) as a prognostic marker that promotes proliferation and metastasis of HCC by binding phosphoinositide-3-Kinase regulatory subunit 1 (PIK3R1) and sprouty-related EVH1 domain containing 2.
|Figure 2: Pictorial flowchart of essential microRNAs involved in the diagnosis, staging, recurrence and survival of hepatocellular carcinoma. The microRNAs reported to be upregulated in hepatocellular carcinoma are etched in green arrows (blue box) whilst those downregulated are illustrated in red arrows (yellow box)|
Click here to view
Upregulation of miR-221 and downregulation of miR-214 are associated with recurrence of HCC., In addition, upregulation of miR-147 and miR-155 and downregulation of miR-19a, miR-886-5p, miR-126, miR-22, and miR-24 have been described to be associated with recurrence following liver transplantation., However, in HBV-induced HCC, miR-29a-5p acts as a marker for the prediction of early tumor recurrence after HCC resection.
Needless to mention, the end-point in cancer research is overall survival. In context, data have predicted an overall shorter survival in HCC by an elevated expression of miR-25, miR-372, miR-155, and miR-182 whereas increased survival has been assessed through downregulation of miR-100, miR-29, miR-10,1and miR-148b.,,,,,,,
| Targeted Therapeutics in Hepatocellular Carcinoma-microRNAs as Key Players|| |
Harnessing the therapeutic potential of miRNAs is nowadays much in vogue. As a common practice in cancer therapy, miRNA antagonists such as chemically modified locked nucleic acids (LNA) or antagomirs have been used to inhibit oncomir activity. These miRNA antagonists bind the oncomirs by base-pairing to inhibit their activity., Studies on animal models have revealed a suppression of the oncomir miR-221 resulting in a significant decrease in tumor number, size, and increased overall survival. Antisense miR-21 co-encapsulated with gemcitabine in PEGylated-PLGA nanoparticles have resulted in increased apoptosis in HCC cell lines. In addition, miravirsen, an anti-miR-122 (a 15-nucleotide LNA) used to treat chronic HCV infection, is currently in phase III clinical trials.
Downregulated miRNA activity is nowadays restored by introducing miRNA mimics in cells. Targeted delivery of miR-375 through gold nanoparticles into primary and xenograft mouse models has been shown to be a significant therapeutic vista. In this regard, the use of liposome-based miR-34 mimics is now evidenced in phase I clinical trials.
In addition, there are reports of miRNA expression influencing HCC chemotherapy. A study elucidated downregulation of 13 miRNAs binding to adenosine triphosphate-binding cassette (ABC) transporters (ABCA1, ABCC1, ABCC5, ABCC10, and ABCE1) to render chemoresistance in HCC cells by efflux of specific drugs from the cells. Studies have opined that a downregulation of miR-223 regulates ABCB1 expression, thereby resulting in multidrug resistance (MDR).
The miRNA expression profile has been found to play a crucial role in the treatment of HCC by interferons (IFNs). Results have shown that an overexpression of miR-146 makes HCC cells resistant to IFN by downregulating SMAD4. However, a decreased expression of miR-26 renders HCC cells sensitive to IFNs. HCC cell lines transfected with anti-miR-21 has been demonstrated to exhibit better clinical response when treated with IFN-α/5-fluorouracil (5-FU) combination therapy. On the other hand, an increased expression of miR-141 in HCC cells is associated with 5-FU resistance, whereas the reverse is true for miR-193a-3p in HCC.,
Administration of sorafenib, a multi-kinase inhibitor against HCC, has been reported to modulate miRNA expression. Sorafenib treatment in HCC cell lines resulted in an upregulation of 14 miRNAs. Overexpression of miR-122 in HCC cell lines makes them more sensitive to sorafenib treatment. Contrarily, decreased expression of miR-34a is an indication of sorafenib resistance. In a recent investigation, an artificial lncRNA was generated to overcome sorafenib resistance of HCC by targeting multiple miRNAs.
Studies indicate that an overexpression of miR-122 in HCC cells makes them sensitive to doxorubicin treatment. This forced expression of miR-122 also increases sensitivity of HCC cells to adriamycin and vincristine by targeting MDR proteins such as ABC, antiapoptotic Bcl-w, and the cell cycle regulator, cyclin B1. Correspondingly, miR-101 in HCC cells is known to inhibit autophagy and enhance cisplatin-induced apoptosis.
Therapeutically, metastamiRs are miRNAs that promote or suppress migration and metastasis of cancer cells, exhibiting significant functional correlation with the prognosis of HCC. Unlike targeted therapy, metastamiRs have been shown to target multiple genes and signaling pathways with an appreciable suppression of cancer metastasis that might futuristically enable an anti-HCC miRNA drug screening and development.
| Conclusions and Future Perspectives|| |
Major unresolved issues in early diagnosis and clinical management of HCC, such as inherent and adaptive resistance to common chemotherapeutics together with its rapidly advancing nature, have made HCC one of the most challenging and life-threatening malignancies to contain. Symptomatic HCC continues to be mortiferous and the late presentation of patients to the clinics renders the probability of curative treatment regimen acutely infinitesimal. Therefore, early diagnosis of HCC is critical for the applicability of potentially curative treatments. On the above framework, advancements in establishing miRNAs as diagnostic and prognostic biomarkers for HCC are imperative. A large number of miRNAs have already been suggested as biomarkers in HCC. However, a universal consensus on the specific set of miRNAs to be used in the diagnosis and prognosis of HCC is yet to be arrived at. In addition, unanimity on the nature of biological samples to be analyzed for achieving desired results on miRNAs is still in wilderness. Furthermore, tumor microenvironment, biological behavior of tumors, and variation and sensitivity of miRNA expression depending on the nature and progression of the disease play a pivotal role in the limitation of the applicability of miRNAs as a potential therapeutic aid.
Any molecule to be used as a biomarker for routine clinical use must have easy and cost-effective detection methods. However, currently employed techniques for detection of miRNAs are deep sequencing, arrays, and quantitative PCR, all of which are not only expensive but also require specialized training skills for result analysis. Therefore, future inquests should aim at developing cheaper user-friendly detection practices to facilitate a better validation and establishment of miRNAs as powerful diagnostic and prognostic screening tools for HCC.
Another challenge in using miRNAs as therapeutic targets would be to reduce the undesired off-target effects. Oncomirs or tumor suppressor miRNAs against HCC may also have various functional implications on other organ systems. Hence, it is important to deliver the miRNA antagonists or miRNA mimics to specific tumor sites rather than redundant locales. In context, in a study by Kota et al., a viral vector system was developed that delivered miR-26 specifically to the tumor site in a mouse model. Therefore, targeted approaches should aim to reduce the probability of deleterious off-target effects of miRNAs.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma – The future is now. Cancer Metastasis Rev 2013;32:229-68.
Chauhan R, Lahiri N. Tissue- and serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer 2016;8 Suppl 1:37-55.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg 2010;8:336-41.
Pillai RS. MicroRNA function: Multiple mechanisms for a tiny RNA? RNA 2005;11:1753-61.
Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011;38:724-33.
Saba R, Gushue S, Huzarewich RL, Manguiat K, Medina S, Robertson C, et al.
MicroRNA 146a (miR-146a) is over-expressed during prion disease and modulates the innate immune response and the microglial activation state. PLoS One 2012;7:e30832.
Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: White matter versus gray matter. Acta Neuropathol 2011;121:193-205.
Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, et al.
Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One 2010;5:e14302.
Law PT, Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:437-49.
Bandopadhyay M, Sarkar N, Datta S, Das D, Pal A, Panigrahi R, et al.
Hepatitis B virus X protein mediated suppression of miRNA-122 expression enhances hepatoblastoma cell proliferation through cyclin G1-p53 axis. Infect Agent Cancer 2016;11:40.
Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al.
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011;104:235-40.
Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, et al.
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget 2015;6:3211-24.
Yu G, Chen X, Chen S, Ye W, Hou K, Liang M. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells. J Transl Med 2016;14:122.
Takata A, Otsuka M, Ohno M, Kishikawa T, Yoshikawa T, Koike K, et al.
Mutual antagonism between hepatitis B viral mRNA and host microRNA let-7. Sci Rep 2016;6:23237.
Chen C, Wu M, Zhang W, Lu W, Zhang M, Zhang Z, et al.
MicroRNA-939 restricts hepatitis B virus by targeting Jmjd3-mediated and C/EBPα-coordinated chromatin remodeling. Sci Rep 2016;6:35974.
Liu D, Wu J, Liu M, Yin H, He J, Zhang B. Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells. Biochem Biophys Res Commun 2015;464:1215-21.
Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: Progression in early diagnosis, prognosis, and personalized therapy. Biomark Res 2013;1:10.
Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, et al.
A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015;16:804-15.
Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.
Zhang Y, Li T, Qiu Y, Zhang T, Guo P, Ma X, et al.
Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5642.
Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, et al.
Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70:9798-807.
Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013;19:7836-45.
El-Abd NE, Fawzy NA, El-Sheikh SM, Soliman ME. Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol Diagn Ther 2015;19:213-20.
Yang N, Li S, Li G, Zhang S, Tang X, Ni S, et al.
The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget 2017;8:3683-95.
Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, et al.
Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med 2015;47:e184.
Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol 2014;9:47.
Liang Z, Gao Y, Shi W, Zhai D, Li S, Jing L, et al.
Expression and significance of microRNA-183 in hepatocellular carcinoma. ScientificWorldJournal 2013;2013:381874.
Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70-3.
Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013;383:49-58.
Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, et al.
Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009;39:786-94.
Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al.
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
Chang RM, Xiao S, Lei X, Yang H, Fang F, Yang LY, et al.
miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma. Clin Cancer Res 2016; doi: 10.1158/1078-0432.CCR-16-0851.
Yoon SO, Chun SM, Han EH, Choi J, Jang SJ, Koh SA, et al.
Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol 2011;42:1391-400.
Wang J, Li J, Wang X, Zheng C, Ma W. Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. Biochem Biophys Res Commun 2013;439:47-53.
Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, et al.
Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012;6:445-57.
Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012;138:153-61.
Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, et al.
MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012;7:e52393.
Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013;375:23-30.
Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012;12:227.
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al.
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010;51:836-45.
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, et al.
MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett 2012;586:4362-70.
Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol 2014;31:984.
Krützfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, et al.
Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007;35:2885-92.
Xi D, Shang J, Fan E, You J, Zhang S, Wang H. Nanopore-based selective discrimination of microRNAs with single-nucleotide difference using locked nucleic acid-modified probes. Anal Chem 2016;88:10540-6.
Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, et al.
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012;56:1025-33.
Devulapally R, Foygel K, Sekar TV, Willmann JK, Paulmurugan R. Gemcitabine and antisense-microRNA co-encapsulated PLGA-PEG polymer nanoparticles for hepatocellular carcinoma therapy. ACS Appl Mater Interfaces 2016;8:33412-22.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al.
Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94.
Xue HY, Liu Y, Liao JZ, Lin JS, Li B, Yuan WG, et al.
Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma. Oncotarget 2016;7:86675-86.
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65.
Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, et al.
Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012;55:821-32.
Yang T, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, et al.
MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2013;238:1024-32.
Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, et al.
miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011;414:675-80.
Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, et al.
Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci 2013;9:303-12.
Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, et al.
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010;103:1617-26.
Shi L, Wu L, Chen Z, Yang J, Chen X, Yu F, et al.
MiR-141 activates Nrf2-dependent antioxidant pathway via down-regulating the expression of keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil. Cell Physiol Biochem 2015;35:2333-48.
Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, et al.
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 2012;287:5639-49.
Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, et al.
microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett 2011;585:1828-34.
Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al.
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009;284:32015-27.
Yang F, Li QJ, Gong ZB, Zhou L, You N, Wang S, et al.
MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 2014;13:77-86.
Tang S, Tan G, Jiang X, Han P, Zhai B, Dong X, et al.
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Oncotarget 2016;7:73257-69.
Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al.
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009;69:5761-7.
Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, et al.
MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011;310:160-9.
Xu Y, An Y, Wang Y, Zhang C, Zhang H, Huang C, et al.
miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2013;29:2019-24.
Wu L, Bai X, Xie Y, Yang Z, Yang X, Lin J, et al.
MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development. Hepatol Res 2017;47:80-94.
Zhu J. DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006;13:265-73.
[Figure 1], [Figure 2]